CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Lenalidomide has been shown to have single agent activity in indolent Non-Hodgkin's Lymphoma. It is approved for the treat-...
Phase 2
Santa Rosa, California, United States and 1 other location
and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma...
Phase 1, Phase 2
Palo Alto, California, United States and 73 other locations
to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...
Phase 3
San Francisco, California, United States and 66 other locations
administered orally in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) admin...
Phase 1, Phase 2
San Francisco, California, United States and 12 other locations
patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas wh...
Phase 1
Santa Rosa, California, United States and 29 other locations
This is a First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin L....
Phase 1
San Francisco, California, United States and 7 other locations
017 works in treating patients with non-Hodgkin's lymphoma whose disease has come back or has not responded to treatment....
Phase 1
San Francisco, California, United States and 13 other locations
A Phase 1/2 Study of bbT369, a dual targeting CAR T cell drug product with a gene edit, in Relapsed and/or Refractory B cell Non-Hodgkin...
Phase 1, Phase 2
Stanford, California, United States and 3 other locations
ATG-031 study (alias: PERFORM) is a multicenter, open-label, Phase 1 study of ATG-031 in patients with advanced solid tumors or B-NHL. The study desi...
Phase 1
San Francisco, California, United States and 3 other locations
gemcitabine, and oxaliplatin (R-GemOx).To evaluate the efficacy of magrolimab in combination with rituximab in participants with indolent lymphoma...
Phase 1, Phase 2
Stanford, California, United States and 19 other locations
Clinical trials
Research sites
Resources
Legal